Theratechnologies (TSE:TH) had its price target lifted by CIBC from C$10.30 to C$15.00 in a research report released on Wednesday morning.

Separately, National Bank Financial reduced their price objective on Theratechnologies from C$9.75 to C$8.75 and set an outperform rating for the company in a research report on Tuesday, November 14th.

Shares of Theratechnologies (TSE TH) opened at C$9.94 on Wednesday. Theratechnologies has a 52-week low of C$4.91 and a 52-week high of C$10.05. The company has a market capitalization of $745.27, a P/E ratio of -39.76 and a beta of 0.52.

Theratechnologies (TSE:TH) last announced its quarterly earnings data on Wednesday, February 7th. The company reported C($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.04) by C($0.02). Theratechnologies had a negative return on equity of 25.45% and a negative net margin of 25.69%. The firm had revenue of C$12.60 million during the quarter, compared to the consensus estimate of C$11.70 million.

TRADEMARK VIOLATION WARNING: “CIBC Raises Theratechnologies (TH) Price Target to C$15.00” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.